JD Health International, Inc.

JD Health International, Inc.

3.24
THB
-0.12
(-3.57%)
446.73BMarket Cap
Mar 29Next Earn
JD Health International, Inc.
SET:JDHEAL19
(Stock Exchange of Thailand)

Recent

price

3.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.04
0.05
0.07
0.18
0.2
0.3
0.35
0.37
0.47
- -
Revenue per Share
- -
- -
-0.01
-0.16
-0.01
- -
0.01
0.03
0.03
- -
Basic EPS, GAAP
- -
- -
- -
0.03
0.02
0.02
0.03
0.03
0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
0.25
0.25
0.28
0.31
0.35
0.38
0.39
Book Value per Share
- -
- -
- -
0.25
0.25
0.27
0.3
0.33
0.36
0.38
Tangible Book Value per Share
155,312
155,312
155,312
109,690
153,713
154,312
155,146
156,089
157,120
3,172
Basic Weighted Avg Shares
5,553
8,169
10,842
19,383
30,682
46,736
53,530
58,160
73,441
- -
Sales/Revenue/Turnover
4.62
3.76
4
1.81
-4.45
-0.1
1.31
2.54
5.37
- -
Operating Margin (%)
3
6
7
27
63
141
227
215
280
- -
Depreciation Expense
179
215
-972
-17,234
-1,074
380
2,142
4,162
5,375
- -
Net Income, GAAP
30.25
29.82
- -
- -
- -
44.92
20.44
13.34
10.99
- -
Effective Tax Rate (%)
3.22
2.63
-8.96
-88.92
-3.5
0.81
4
7.16
7.32
- -
Profit Margin (%)
654
736
7,079
38,023
37,700
40,091
33,265
42,939
35,607
36,467
Working Capital
2
2
6
61
134
129
119
149
429
609
LT Debt
663
749
-459
39,251
39,855
44,785
49,370
55,241
60,073
61,456
Total Equity
- -
29.95
- -
- -
- -
-0.19
1.05
1.91
5.79
- -
Return on Invested Capital (%)
- -
30.32
- -
- -
- -
0.9
4.54
7.94
9.28
- -
Return on Capital (%)
- -
30.45
- -
- -
-2.71
0.9
4.55
7.96
9.32
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
154
207
266
LT Borrowings
- -
- -
- -
LT Finance Leases
276
429
609
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
158,939
159,394
158,414
Market Capitalization
- -
162,829
91,217

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
58,228
56,349
58,107
Cash, Cash Equivalents & STI
49,306
48,151
49,273
Accounts Receivable, Net
391
430
536
Inventories
7,455
6,858
7,384
Total Current Liabilities
19,910
20,741
21,640
Payables & Accruals
- -
- -
- -
ST Debt
154
207
266
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.96%
8.75%
Free Cash Flow
- -
31.5%
133.85%
Net Income, GAAP
- -
71.56%
29.16%
Sales/Revenue/Turnover
- -
32.02%
26.28%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
58,160
2025
- -
- -
73,441
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.03
2025
- -
- -
0.03
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
JD Health International Inc. operates as a technology-driven online healthcare platform and retail pharmacy company primarily serving the Chinese market. The company’s core products and services include pharmaceutical and healthcare product sales; online consultation and prescription renewal; chronic disease management; family doctor services; consumer healthcare products; home care services such as wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical insurance payment services; smart healthcare and digital health solutions; smart monitoring and respiratory therapy devices; senior-oriented medical devices; home medical device setup and support including blood glucose meters and oxygen generators; rapid testing products; and online marketing services targeted at advertisers. Its retail pharmacy business operates through direct sales, an online marketplace, and an omnichannel model. The company also offers a platform for doctors to practice multisite, manage patients, conduct healthcare research, and exchange academic and clinical knowledge. JD Health strategically focuses on integrating pharmaceutical supply chain services with comprehensive healthcare offerings across user lifespans. Its geographic operations include extensive reach within China, supported by a strong logistics network enabling market-leading 24-hour prescription delivery. Founded in 2018, JD Health is headquartered in Beijing, China and functions as the healthcare unit of JD.com. In the past 1-2 years, JD Health has pursued multiple strategic partnerships and expansions. Notably, it forged a strategic cooperation agreement with Boehringer Ingelheim Animal Health to leverage pharmaceutical supply chain strength for pet healthcare services. It also announced a strategic partnership with INTCO Medical to co-develop high-end customized medical products via a Customer-to-Manufacturer model, aiming to innovate medical protection ecosystems and enhance user safety and convenience. These partnerships underline JD Health’s commitment to expanding product innovation and accelerating growth in trending healthcare products. Additionally, JD Health has actively expanded offline pharmacy networks to digitize traditional brick-and-mortar pharmacies. The company continuously enhances its digital health and e-commerce capabilities, reinforcing its position in China’s rapidly growing online healthcare and retail pharmacy sectors. Overall, JD Health International Inc. combines online pharmaceutical retail, healthcare services, digital health technologies, and strategic industry partnerships to serve consumer and professional healthcare markets within China, emphasizing innovation and comprehensive service offerings across healthcare verticals. This description integrates the company’s detailed product and service portfolio, geographic and business scope, and noteworthy recent corporate developments and strategic alliances up to 2025.

Company News

  • JD Health International Inc. (JDHIY) Q4 2025 Earnings Call Transcript

  • JD Health International Inc. (JDHIF) Q2 2025 Earnings Call Transcript

  • JD Health International Inc. (JDHIF) Q4 2024 Earnings Call Transcript

  • JD Health: Becoming Bullish On Tailwinds And Catalysts (Rating Upgrade)

  • JD Health International Inc. (JDHIF) Q4 2023 Earnings Call Transcript

  • Don't Miss the Boom: 3 Pharma Stocks Set to Explode Higher

  • JD Health International Inc. (JDHIF) Q4 2022 Earnings Call Transcript